Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide product sales ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail
Latest, FY2025
4,414
Period ended Dec 31, 2025
Change on a year earlier
+0.9%
4,374 in FY2024
History
11 years
Since FY2015
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4,414 | +0.9% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 4,374 | +8.1% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 4,048 | +11.6% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 3,628 | +11.7% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 3,248 | +17.6% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 2,763 | +3.4% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 2,672 | +16.6% | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 2,291 | +16.4% | Form 10-K (filed 2021-02-09) ↗ |
| FY2017 | Dec 31, 2017 | 1,968 | +20.4% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 1,635 | +24.6% | Form 10-K (filed 2019-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 1,312 | – | Form 10-K (filed 2018-02-13) ↗ |
Breakdown
What makes up prolia (denosumab — postmenopausal osteoporosis) — worldwide product sales ($m)
- Prolia (denosumab — Postmenopausal Osteoporosis) — U.S. product sales ($M)2,978 · FY2025
- Prolia (denosumab — Postmenopausal Osteoporosis) — Rest of World (ROW) product sales ($M)1,436 · FY2025
- Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide reported sales growth YoY (%)1.0% · FY2025
- Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide net selling price change YoY (%)–
Cite this data
StockData. (2026). Amgen Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide product sales ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_prolia_ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.